Craig Gracey, serving as the Chief Accounting Officer for Omada Health, Inc., has completed a transaction involving the sale of 6,894 shares of the company's common stock on June 12, 2026. The aggregate value of these transactions reached $120,123. The execution of these sales occurred at a weighted average price of $17.4243 per share. The transaction was not a single block sale but was executed across multiple trades, with individual share prices ranging from $17.04 to $17.71.
This activity was conducted pursuant to a 10b5-1 trading plan, a pre-arranged framework designed to facilitate insider trading in compliance with securities regulations. Mr. Gracey originally adopted this specific plan on March 13, 2026. Following the completion of this sale, Mr. Gracey's direct holdings in Omada Health common stock stand at 9,191 shares.
The timing of this insider transaction coincides with notable movement in Omada Health's stock price. Over the preceding six months, the company's shares have delivered a 19% return to shareholders. However, market analysis indicates that the stock currently trades above its InvestingPro Fair Value estimate. This valuation metric places Omada Health among the group of overvalued stocks identified within the healthcare sector.
Despite the valuation concerns, analyst outlooks remain constructive. According to data from InvestingPro Tips, market analysts predict the company will achieve profitability in the current year. This positive outlook is supported by recent revisions from four analysts who have raised their earnings estimates upwards. Furthermore, Omada Health recently reported its financial results for the first quarter of 2026. The company reported an earnings per share of -$0.05, which exceeded the projected loss of -$0.08. Revenue for the quarter reached $78 million, marking a significant 42% increase compared to the same period in the previous year.
Corporate governance updates also accompanied these financial disclosures. Omada Health held its 2026 Annual Meeting of Stockholders, during which Sean Duffy and Trevor Fetter were elected as Class I Directors. These newly elected directors will serve terms extending until the 2029 annual meeting. In the broader analyst community, Citizens raised its price target for Omada Health to $21 from $18, while maintaining a Market Outperform rating. Analyst Constantine Davides from Citizens noted that the stock has been trading at 2.5 times the firm's 2026 revenue estimate since the company's initial public offering in June 2025.